Home>>Signaling Pathways>> Others>> Nitric Oxide>>Carboxy-PTIO, potassium salt

Carboxy-PTIO, potassium salt

(Synonyms: 2-4-羧苯基四甲基咪唑烷-1-氧-3-氧化物) 目录号 : GC16211

Carboxy-PTIO potassium salt是一种一氧化氮(NO)清除剂。

Carboxy-PTIO, potassium salt Chemical Structure

Cas No.:148819-94-7

规格 价格 库存 购买数量
5mg
¥477.00
现货
10mg
¥816.00
现货
50mg
¥2,818.00
现货
100mg
¥5,144.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

Description

Carboxy-PTIO potassium salt is a nitric oxide (NO) scavenger[1]. Carboxy-PTIO potassium salt can react stoichiometrically with NO and can be used for EPR detection of NO[2].

In vitro, pretreatment of A375-S2 cells with Carboxy-PTIO potassium salt (200µM) for 1h significantly inhibited physalin A-stimulated NO expression, reduced procaspase-3 and PARP cleavage, reversed the decrease in mTOR and p-mTOR levels, and also inhibited in the cells Conversion of LC3 I to LC3 II [3]. Pretreating HUVEC cells with Carboxy-PTIO potassium salt (100µM) for 6 hours significantly enhanced the inhibitory effect of IL-1β on PGIS [4]. Carboxy-PTIO potassium salt (0.5µM, 1µM) pretreated MDA-MB-231 cells for 1 hour, which significantly reduced the inhibitory activity of compounds 3a-f on cells [5].

In vivo, intravenous injection of Carboxy-PTIO potassium salt (0.3-1.2 mg/kg) in mice with cerebral ischemic injury resulted in a dose-dependent reduction in the incidence of cerebral infarction by 27% even when treatment was delayed for up to 4 hours. -30%[6]. Carboxy-PTIO potassium salt (0.056-1.70mg/kg/min) was injected intravenously for 60 minutes to treat endotoxic shock rats, which significantly improved the symptoms of hypotension and renal insufficiency in rats and avoided the shock state [7].

References:
[1]Pfeiffer S, Leopold E, Hemmens B, et al. Interference of carboxy-PTIO with nitric oxide-and peroxynitrite-mediated reactions[J]. Free Radical Biology and Medicine, 1997, 22(5): 787-794.
[2]T Akaike, et al. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry. 1993 Jan 26;32(3):827-32.
[3] He H, Feng Y S, Zang L H, et al. Nitric oxide induces apoptosis and autophagy; autophagy down-regulates NO synthesis in physalin A-treated A375-S2 human melanoma cells[J]. Food and chemical toxicology, 2014, 71: 128-135.
[4] Camacho M, LÓpez-Belmonte J, Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity[J]. Circulation research, 1998, 83(4): 353-365.
[5] Kang F, Zhu J, Wu J, et al. O 2-3-Aminopropyl diazeniumdiolates suppress the progression of highly metastatic triple-negative breast cancer by inhibition of microvesicle formation via nitric oxide-based epigenetic regulation[J]. Chemical Science, 2018, 9(34): 6893-6898.
[6]Lee E J, Hung Y C, Chen H Y, et al. Delayed treatment with carboxy-PTIO permits a 4-h therapeutic window of opportunity and prevents against ischemia-induced energy depletion following permanent focal cerebral ischemia in mice[J]. Neurochemical research, 2009, 34: 1157-1166.
[7]Yoshida M, Akaike T, Wada Y, et al. Therapeutic effects of imidazolineoxyl N-oxide against endotoxin shock through its direct nitric oxide-scavenging activity[J]. Biochemical and biophysical research communications, 1994, 202(2): 923-930.

Carboxy-PTIO potassium salt是一种一氧化氮(NO)清除剂[1]。Carboxy-PTIO potassium salt可与NO发生化学计量反应,可用于NO的EPR检测[2]。

在体外,Carboxy-PTIO potassium salt(200µM)预处理A375-S2细胞1h,显著抑制physalin A刺激的NO表达,减少procaspase-3和PARP裂解,逆转mTOR和p-mTOR水平降低,还抑制细胞中的LC3 I向LC3 II转化[3]。Carboxy-PTIO potassium salt(100µM)预处理HUVEC细胞6h,显著增强了IL-1β对PGIS的抑制作用[4]。Carboxy-PTIO potassium salt(0.5µM,1µM)预处理MDA-MB-231细胞1h,显著降低了化合物3a-f对细胞的抑制活性[5]。

在体内,Carboxy-PTIO potassium salt(0.3-1.2 mg/kg)静脉注射治疗脑缺血性损伤小鼠,即使治疗延迟长达4小时,脑梗塞的发生率也呈剂量依赖性减少,降低了27-30% [6]。Carboxy-PTIO potassium salt(0.056-1.70mg/kg/min)通过静脉注射持续60min治疗内毒素休克大鼠,明显改善了大鼠低血压、肾功能不全症状,并且避免了休克状态[7]。

实验参考方法

Cell experiment [1]:

Cell lines

A375-S2 cells

Preparation Method

A375-S2 cells were pre-treated with 1400W (200µM) or Carboxy-PTIO potassium salt (200µM) for 1 h prior to 15µM physalin A treatment for 24 h.

Reaction Conditions

200µM; 1 h

Applications

The inhibitor of nitric oxide synthase 1400W and NO scavenger Carboxy-PTIO potassium salt significantly suppressed the stimulation of NO expression induced by physalin A treatment.

Animal experiment [2]:

Animal models

C57BL/10J mice

Preparation Method

animals was assigned to receive Carboxy-PTIO potassium salt (0.3-1.2 mg/kg; i.p.) or the same volume of saline at the time of MCA occlusion. The right femoral artery was cannulated for measuring arterial blood gases,glucose, hematocrit, and blood pressure before and 45 min after the induction of cerebral ischemia.

Dosage form

0.3-1.2 mg/kg;i.p.

Applications

Mice treated with Carboxy-PTIO potassium salt had dose-specifically reduced brain infarction, significantly by 27-30%, even when therapy was delayed up to 4 h after the ischemic insult.

References:

[1] He H, Feng Y S, Zang L H, et al. Nitric oxide induces apoptosis and autophagy; autophagy down-regulates NO synthesis in physalin A-treated A375-S2 human melanoma cells[J]. Food and chemical toxicology, 2014, 71: 128-135.
[2] Lee E J, Hung Y C, Chen H Y, et al. Delayed treatment with carboxy-PTIO permits a 4-h therapeutic window of opportunity and prevents against ischemia-induced energy depletion following permanent focal cerebral ischemia in mice[J]. Neurochemical research, 2009, 34: 1157-1166.

化学性质

Cas No. 148819-94-7 SDF
别名 2-4-羧苯基四甲基咪唑烷-1-氧-3-氧化物
化学名 2-(4-carboxyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazolyl-1-oxy-3-oxide, monopotassium salt
Canonical SMILES CC(C1(C)C)(N(=C(N1[O])C2=CC=C(C([O-])=O)C=C2)=O)C.[K+]
分子式 C14H16KN2O4 分子量 315.38
溶解度 >1.4 mg/ml in DMSO, >3.3 mg/ml in DMF, >1.6mg/ml in Ethanol 储存条件 Desiccate at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 3.1708 mL 15.8539 mL 31.7078 mL
5 mM 0.6342 mL 3.1708 mL 6.3416 mL
10 mM 0.3171 mL 1.5854 mL 3.1708 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

产品文档

Quality Control & SDS

View current batch: